Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;11(6):352-62.
doi: 10.1038/nrendo.2015.26. Epub 2015 Mar 3.

Chylomicronaemia--current diagnosis and future therapies

Amanda J Brahm  1 , Robert A Hegele  1
Affiliations
Review

Chylomicronaemia--current diagnosis and future therapies

Amanda J Brahm et al. Nat Rev Endocrinol. 2015 Jun.

Abstract

This Review discusses new developments in understanding the basis of chylomicronaemia--a challenging metabolic disorder for which there is an unmet clinical need. Chylomicronaemia presents in two distinct primary forms. The first form is very rare monogenic early-onset chylomicronaemia, which presents in childhood or adolescence and is often caused by homozygous mutations in the gene encoding lipoprotein lipase (LPL), its cofactors apolipoprotein C-II or apolipoprotein A-V, the LPL chaperone lipase maturation factor 1 or glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1. The second form, polygenic late-onset chylomicronaemia, which is caused by an accumulation of several genetic variants, can be exacerbated by secondary factors, such as poor diet, obesity, alcohol intake and uncontrolled type 1 or type 2 diabetes mellitus, and is more common than early-onset chylomicronaemia. Both forms of chylomicronaemia are associated with an increased risk of life-threatening pancreatitis; the polygenic form might also be associated with an increased risk of cardiovascular disease. Treatment of chylomicronaemia focuses on restriction of dietary fat and control of secondary factors, as available pharmacological therapies are only minimally effective. Emerging therapies that might prove more effective than existing agents include LPL gene therapy, inhibition of microsomal triglyceride transfer protein and diacylglycerol O-acyltransferase 1, and interference with the production and secretion of apoC-III and angiopoietin-like protein 3.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Lipid Res. 2013 May;54(5):1369-84 - PubMed
    1. Ann N Y Acad Sci. 1993 Jun 14;683:16-34 - PubMed
    1. Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):423-37 - PubMed
    1. Pharmacotherapy. 2014 Sep;34(9):961-72 - PubMed
    1. Lipids Health Dis. 2007 Sep 20;6:23 - PubMed

Publication types

MeSH terms